{"product_id":"guardianpharmacy-five-forces-analysis","title":"Guardian Pharmacy Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGuardian Pharmacy’s Porter's Five Forces snapshot highlights competitive rivalry, supplier and buyer leverage, substitute threats, and barriers to entry shaping its margins and growth prospects; strategic levers emerge from pricing power to supply-chain resilience. This brief whets the appetite—unlock the full Porter's Five Forces Analysis for force-by-force ratings, visuals, and actionable strategy to inform investment or operational decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidated drug wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS drug distribution is dominated by three wholesalers—McKesson, AmerisourceBergen and Cardinal Health—which together control roughly 85–90% of distribution; McKesson reported about $263B, AmerisourceBergen ~$238B and Cardinal Health ~$167B in 2024 revenue. This concentration gives suppliers strong leverage over price, payment terms and fees. Guardian must balance cost, fill rate and credit with few alternatives; long-term contracts lower volatility but reduce flexibility. Any disruption or fee increase can quickly compress margins across the network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand manufacturers’ pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent-protected brands and limited-source specialty drugs now account for roughly 50% of US drug spend and retain strong list-price power; average manufacturer rebates on branded drugs were about 28% in 2023–24, which helps but does not eliminate list-price pressure. Short-dated inventory and limited allocations increase working-capital needs and can raise days inventory outstanding by weeks. Volume via GPOs boosts negotiation clout but exclusives constrain pricing flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric supply volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMulti-source generics generally temper supplier power, but periodic shortages have pushed select generic prices sharply higher; FDA shortages remained elevated through 2023–24. Roughly 70% of active pharmaceutical ingredient capacity is concentrated in China and India, creating bottleneck risk when regulators act or sites fail inspections. Guardian’s formulary management and secondary sourcing cut exposure and stabilize costs, yet abrupt manufacturer exits can still compress pharmacy margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePackaging and automation vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePackaging and automation vendors hold strong supplier power for Guardian Pharmacy because unit-dose\/blister packaging, strip-pouch robots and eMAR integrations are mission-critical; 2024 industry reports confirm these systems drive core dispensing accuracy and workflow continuity, making vendor switches costly due to retraining, interface rework and downtime. Service contracts and consumables create semi-captive spend, while standardization across sites recovers scale discounts but narrows vendor choice.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMission-critical: unit-dose\/blister, strip-pouch, eMAR\u003c\/li\u003e\n\u003cli\u003eHigh switching costs: workflow, training, interfaces\u003c\/li\u003e\n\u003cli\u003eSemi-captive spend: service contracts \u0026amp; consumables\u003c\/li\u003e\n\u003cli\u003eStandardization: scale discounts vs reduced vendor diversity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical software and data interfaces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical software and eMAR connectivity for LTC requires vendor-specific interfaces, creating integration complexity. Integration fees commonly range from $10,000 to $75,000 with annual maintenance or hosting charges around 10–20% of license value. Limited compatible options concentrate dependence—top three LTC platforms cover roughly 60% of the US market in 2024. ONC Cures Act interoperability rules strengthen leverage but enforcement remains uneven.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegration cost: $10k–$75k\u003c\/li\u003e\n\u003cli\u003eAnnual maintenance: 10–20%\u003c\/li\u003e\n\u003cli\u003eTop 3 vendors ≈60% LTC market (2024)\u003c\/li\u003e\n\u003cli\u003eONC Cures Act (2023–24) improves standards; enforcement inconsistent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop 3 wholesalers control \u003cstrong\u003e~85-90%\u003c\/strong\u003e; brand rebates \u003cstrong\u003e~28%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThree wholesalers (McKesson $263B, AmerisourceBergen $238B, Cardinal $167B) control ~85–90% distribution, giving suppliers pricing\/fee leverage; brand drugs (~50% of spend) with ~28% average rebates sustain list-price power. API concentration (~70% China\/India) and FDA shortages (elevated 2023–24) raise supply risk; packaging\/eMAR vendors and integration costs ($10k–$75k; 10–20% maintenance) create high switching costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e85–90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 revenues\u003c\/td\u003e\n\u003ctd\u003eMcK\/ABC\/Card\u003c\/td\u003e\n\u003ctd\u003e$263B\/$238B\/$167B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrands\u003c\/td\u003e\n\u003ctd\u003e% of spend\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates\u003c\/td\u003e\n\u003ctd\u003eAvg\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\u003c\/td\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003e~70% China\/India\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration\u003c\/td\u003e\n\u003ctd\u003eCost\/maint\u003c\/td\u003e\n\u003ctd\u003e$10k–$75k \/ 10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter’s Five Forces analysis for Guardian Pharmacy revealing competitive rivalry, buyer\/supplier power, entry barriers, and substitutes, highlighting emerging threats and strategic levers to protect margin and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear, one-sheet summary of Guardian Pharmacy's Porter's Five Forces—perfect for quick decision-making and relieving strategic uncertainty. Customize pressure levels and swap in your own data to reflect regulatory shifts or new entrants without complex tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLTC and SNF operator consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge multi-facility LTC and SNF groups negotiate aggressively on price, service levels, and penalties, leveraging centralized RFPs and multi-state footprints to extract better terms; about 15,000 U.S. nursing homes (2024) concentrate purchasing power. Guardian must tailor measurable clinical programs and reporting to win enterprise deals, since losing a chain can materially cut regional volumes and revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPOs and procurement savvy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGPO membership standardizes pricing expectations and compresses margins, with roughly 90% of US hospitals using GPOs to centralize purchases. Benchmarking across pharmacies drives frequent rebids, typically every 12–24 months, intensifying price pressure. Volume commitments are routinely traded for pricing concessions and rebates. Guardian leverages scale and outcomes data to defend value in these negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching costs vs. service stickiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eeMAR integration, cycle-fill calendars, and staff training raise tangible switching costs for clients by embedding Guardian Pharmacy into EHR workflows and daily operations; 2024 industry data show digital integration is a primary retention driver. Buyers still defect for better pricing, accuracy lapses, or survey-readiness gaps. On-site support and med-pass optimization create durable retention moats, while performance guarantees and KPI-based contracts increasingly determine renewals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement pressure pass-through\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpreimbursement pressure pass-through: in tighter medicare budgets and pdpm cost controls push snf operators to demand lower pharmacy spend favor generics deprescribing guardian clinical interventions that cut hospitalizations can validate a price premium transparent reporting helps align incentives amid constrained facility budgets.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: PDPM-driven rate scrutiny increases demand for lower pharmacy costs\u003c\/li\u003e\n\u003cli\u003eGenerics\/deprescribing prioritized under budget pressure\u003c\/li\u003e\n\u003cli\u003eGuardian clinical impact reduces readmissions, supports premium\u003c\/li\u003e\n\u003cli\u003eTransparent reporting aligns payer-provider incentives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/preimbursement\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand predictability and volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCensus fluctuations and case-mix shifts in 2024 drive volatile order volumes and tighter delivery cadence, increasing customer leverage as buyers demand rapid scaling and surge capacity without service degradation. Route optimization and decentralized pharmacy footprints are now essential to meet SLAs, while reliable STAT coverage remains a critical selection factor for customers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand volatility: 2024-driven surge expectations\u003c\/li\u003e\n\u003cli\u003eOperational need: route optimization \u0026amp; decentralization\u003c\/li\u003e\n\u003cli\u003eService KPI: STAT reliability as selection criterion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLTC consolidation, GPO dominance and PDPM cuts force price-driven generics adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge multi-facility LTC\/SNF groups (≈15,000 US nursing homes, 2024) wield centralized RFPs to demand lower prices and service guarantees.\u003c\/p\u003e\n\u003cp\u003eGPO penetration (~90% of US hospitals) standardizes buying, shortens rebid cycles (12–24 months) and compresses margins.\u003c\/p\u003e\n\u003cp\u003ePDPM and Medicaid\/Medicare budget pressure in 2024 boosts demand for generics and cost pass-throughs; Guardian’s outcomes data support premium pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNursing homes\u003c\/td\u003e\n\u003ctd\u003e≈15,000\u003c\/td\u003e\n\u003ctd\u003eConcentrated leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO use\u003c\/td\u003e\n\u003ctd\u003e≈90%\u003c\/td\u003e\n\u003ctd\u003ePrice standardization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebid freq\u003c\/td\u003e\n\u003ctd\u003e12–24 mo\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGuardian Pharmacy Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Guardian Pharmacy Porter's Five Forces analysis you'll receive immediately after purchase—no surprises or placeholders. The document displayed is the final, professionally formatted file, ready for download and use the moment you buy. You're viewing the actual deliverable and will get instant access to this same document upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162970730873,"sku":"guardianpharmacy-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/guardianpharmacy-five-forces-analysis.png?v=1762712362","url":"https:\/\/portersfiveforce.com\/products\/guardianpharmacy-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}